Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fipravirimat - ViiV Healthcare

Next Previous
Drug Profile

Fipravirimat - ViiV Healthcare

Alternative Names: 3640254; BMS 986197; GSK-254; GSK-3640254

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer GSK; ViiV Healthcare
  • Class Antiretrovirals
  • Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 08 Sep 2023 ViiV Healthcare terminates the phase IIb DYNAMIC trial for HIV infections (Combination therapy, Treatment-naïve) in US, Argentina, Canada, France, Germany, Italy, Portugal, Puerto Rico, South Africa and Spain (PO), due to company strategy for portfolio progression (NCT04900038)
  • 29 May 2023 ViiV Healthcare terminates phase II trials in HIV infections (Combination therapy, Treatment-naive) in Switzerland, Spain, Russia, South Africa, Italy, Germany, Canada, Argentina, USA (PO) (NCT04493216)
  • 02 May 2023 Discontinued - Phase-I for HIV infections (Combination therapy, In volunteers) in USA (PO) (GSK pipeline, April 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top